
Oct. 17, 2007 -
Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for
JANUVIA™ (sitagliptin), the only DPP-4 inhibitor available in the United States for the treatment of
type 2 diabetes. JANUVIA is indicated, as an adjunct to diet and exercise, to improve
glycemic control in adult patients with
type 2 diabetes. JANUVIA should not be used in patients with
type 1 diabetes or for the treatment of
diabetic ketoacidosis. JANUVIA has not been studied in combination with
insulin....
Merck's Press Release -